FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38652676.
- Also identified by DOI 10.1158/1078-0432.CCR-24-0460.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Expansion of conventional dendritic cells via FMS-like tyrosine kinase 3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. In this study, we discuss the results of a clinical trial using GS-3583, an FMS-like tyrosine kinase 3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia. See related article by Tolcher et al., p. 2954.
Medical subject headings
- fms-Like Tyrosine Kinase 3
- Hematologic Neoplasms
- Leukemia, Myeloid, Acute